Australia ’s Therapeutic
Goods Administration (TGA) has
announced this year’s first batch of
new chemical entities (NCEs).
Seven NCEs have been registered
in Jan: Lenvima (lenvatinib) by
Esai, Lynparza (olaparib) by AZ
and Opdivo (nivolumab) by BMS
for different cancers, Entresto/
Valsartan (sacubitril/valsartan)
by Novartis for CHF, Genvoya
(tenofovir combination) from
Gilead for HIV, Strensiq (asfotase
alfa rch) from Alexion for enzyme
replacement and Movantik
(naloxegol) by AZ for constipation.
For more go to www.tga.gov.au.The above article was sent to subscribers in Pharmacy Daily's issue from 17 Feb 16 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 17 Feb 16
IN WESTERN Australia, Michael’s Chemist Group has started stocking therapeutic Nicotine Vaping Products (NVPs), pursuant to the Federal Government’s new vaping laws (PD 25 Mar).
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.